Globus Medical reported second quarter 2026 financial results on August 6, 2026. Worldwide net sales increased 5.9% to $789.6 million, driven by a 14% rise in International Spine and 7% growth in US Spine. GAAP diluted EPS was $1.10, down 26.2% from the prior year due to a $110.5 million bargain purchase gain recognized in 2025 related to the Nevro acquisition. Non-GAAP diluted EPS rose 55.8% to $1.34. The company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP fully diluted EPS guidance to a range of $4.95 to $5.05 from the previous $4.70 to $4.80. Globus Medical is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs in spine, orthopedic trauma, joint reconstruction, and biomaterials.

At its 2026 Annual Meeting, Globus Medical, Inc. stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the total authorized shares under the plan by 1,000,000 to a total of 12,000,000 shares of Class A Common Stock. The meeting also resulted in the election of two Class II directors and the ratification of Deloitte & Touche LLP as the company's independent registered public accounting firm.